Track the Kairos Pharma, LTD. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Market capitalisation: €10m. The latest transaction was filed on 30 December 2025 (Attribution). Among the most active insiders: Bhowmick Neil. Every trade is free.
9
Insider Decl.
n/a
Thresholds
€9,315
3 ops.
Buy Volume
n/a
n/a
Sell Volume
49Σ signal
Buys €9,315n/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
4,000 shares@ US$1.44100.0% of flowCOMMON STOCKSEC:0001493152-24-047261:0
Canonical exit: 18 Feb 2025 (T+90)
9 of 9 declarations
About Kairos Pharma, LTD.
Kairos Pharma, LTD. is a pharmaceutical company listed on the XNAS market, specializing in the development of innovative treatments. It focuses on the research and commercialization of therapeutic solutions for various diseases.